Efficacy studies

CRST’s clinical experience covers many pharmacodynamic variables in for example CNS, cardiovascular and metabolic disorders. Surrogate endpoints used in pharmacodynamic studies are typically molecular biomarkers in biological fluids, imaging biomarkers, or clinical physiological or neuropsychological measures.

CRST has experience from early phase I-IIa trials as the sole study site and from later, phase II-IV multi-centre studies as a clinical study site. CRST has most extensive experience in CNS and cardiovascular and metabolic disorders, but has gained relevant experience in many other therapy areas by networking with experts at Turku University Hospital and private clinics.